Related Experiment Video
Updated: Jun 18, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
[Diagnostics and therapy of hepatitis]
1Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Carl-Neuberg-Strasse 1, 30625, Hannover, Deutschland. Strassburg.christian@mh-hannover.de
Der Internist
|November 19, 2009
Summary
Viral hepatitis impacts over a million Germans. Effective treatments exist for hepatitis B and C, with hepatitis C offering potential viral elimination. Hepatitis A is vaccine-preventable, while D and E require further research and treatment options.
Area of Science:
- Hepatology
- Infectious Diseases
- Public Health
Context:
- Viral hepatitis poses a significant public health challenge in Germany, affecting approximately 800,000 to 1 million individuals with chronic hepatitis B or C.
- Clinical management of viral hepatitis is a daily priority for healthcare professionals.
Purpose:
- To provide an overview of the current landscape of viral hepatitis management in Germany.
- To highlight advances in treatment strategies for hepatitis B and C.
- To discuss the status of hepatitis A, D, and E, including diagnostic and therapeutic challenges.
Summary:
- Hepatitis B treatment involves potent antivirals for viral suppression, necessitating long-term strategic planning to prevent resistance.
- Hepatitis C treatment is increasingly individualized, with potential for viral elimination in 50-90% of patients.
- Hepatitis D is underdiagnosed and lacks curative options, often linked to migration. Hepatitis A is vaccine-preventable and non-chronic. Hepatitis E can present chronic courses in specific populations, with no current vaccine.
Impact:
- Advances in hepatitis B and C management offer improved patient outcomes and potential for viral clearance.
- The need for strategic planning in long-term hepatitis B treatment is emphasized.
- Further research and development are crucial for hepatitis D and E, particularly regarding diagnosis and effective therapies.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...